0000950170-23-067358.txt : 20231201
0000950170-23-067358.hdr.sgml : 20231201
20231201163005
ACCESSION NUMBER: 0000950170-23-067358
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231129
FILED AS OF DATE: 20231201
DATE AS OF CHANGE: 20231201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dorval Allison
CENTRAL INDEX KEY: 0001625110
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 231459951
MAIL ADDRESS:
STREET 1: C/O INSULET CORPORATION
STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200
CITY: BILLERICA
STATE: MA
ZIP: 01821
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
ownership.xml
4
X0508
4
2023-11-29
0001840574
Verve Therapeutics, Inc.
VERV
0001625110
Dorval Allison
C/O VERVE THERAPEUTICS
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
false
true
false
false
Chief Financial Officer
false
Common Stock
2023-11-29
4
M
false
1875
A
4614
D
Common Stock
2023-11-29
4
S
false
554
11.45
D
4060
D
Restricted Stock Units
2023-11-29
4
M
false
1875
0
D
Common Stock
1875
3750
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
Includes 553 shares of the Company's common stock acquired in 2023 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 9, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
On November 29, 2021, the reporting person was granted 7,500 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on November 29, 2022 and the remainder vesting in equal annual installments until November 29, 2025.
/s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval
2023-12-01